Therawis Diagnostics GmbH is a privately held oncology-focused company with offices located in Munich, Germany, and was founded together with clinicians and scientists of the Technical University of Munich in September 2015. Therawis Diagnostics GmbH develops and aims at to commercialize a comprehensive portfolio of predictive diagnostics to guide the optimal therapy for breast cancer patients.

These predictive assays will help to address unmet medical needs and major challenges in breast cancer therapy:

  • To predict whether a patient will respond to standard-of-care systemic cancer therapy and if not

  • to switch to an alternative cancer treatment option

Contact:

Therawis Pharma GmbH

Therawis Diagnostics GmbH

Grillparzerstrasse 14

81675 Munich Germany

Tel.: +49 (0) 89 41 42 45 570

Fax. +49 (0) 89 41 42 45 57 40

E-Mail: info@therawis.com

Website: http://www.therawis.com

 

Where to meet us:

< 2018 >
February
  • 21

    All day
    2018.02.21

    United Scientific Group is hosting International Conference on Biomarker Research in Clinical Medicine, scheduled for February 19-21, 2018 in beautiful and dazzling city of Paris, France. BRCM-2018 will uncover different facets of Biomarker study from research to therapy and its applications in divergent fields of Clinical Sciences.

    Presenter: Prof. Wilhelm

  • 22

    13:00 -14:00
    2018.02.22Europe/Berlin

    A clinical view on PITX2 DNA methylation in high-risk breast cancer

    Thursday, Feb. 22, 2018 at 1:00 p.m. CET

    Presenter: Prof. Wilhelm

© 2018 Therawis - All Rights Reserved